Association between patient's age and the utility of prognostic markers after pancreaticoduodenectomy for pancreatic cancer

Optimizing treatments balancing prognosis and therapeutic invasiveness is important in the management of pancreatic cancer (PC) owing to global ageing. This study aimed to verify the different utility of biomarkers by patients’ age. This is a single-center, retrospective cohort analysis involving 16...

Full description

Saved in:
Bibliographic Details
Published inAsian journal of surgery Vol. 46; no. 8; pp. 3052 - 3057
Main Authors Sato, Asahi, Masui, Toshihiko, Kaneda, Akihiro, Yogo, Akitada, Uchida, Yuichiro, Anazawa, Takayuki, Nagai, Kazuyuki, Hatano, Etsuro
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.08.2023
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Optimizing treatments balancing prognosis and therapeutic invasiveness is important in the management of pancreatic cancer (PC) owing to global ageing. This study aimed to verify the different utility of biomarkers by patients’ age. This is a single-center, retrospective cohort analysis involving 160 patients who undertook pancreaticoduodenectomy (PD) for PC. After comparing clinicopathological factors and survival after PD between aged (≥70 y/o) and young (<70 y/o) patients, we compared neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), controlling nutrition (CONUT) score, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19–9 as well as clinicopathological factors between long and short survivors in each group. We also performed Kaplan-Meyer analysis between patients stratified by biomarkers. Overall survival (OS) was significantly worse in aged patients (p = 0.002). In aged patients, CEA was significantly higher in short survivors. In young patients, CONUT score and CA19-9 were higher in short survivors. Kaplan-Meyer analysis showed that NLR and CEA stratified OS in aged patients, whereas CONUT score and CA19-9 could stratify OS in young patients. Our current results suggest that these biomarkers had different impact on survivals according to the patients’ age.
ISSN:1015-9584
0219-3108
DOI:10.1016/j.asjsur.2022.10.009